fbpx
close read more
News

Coronavirus Information (COVID-19)

20/03/2020

Coronavirus Information (COVID-19)

In the context of the health crisis linked to the spread of the COVID 19 virus, the Servier group’s main concern is the health and safety of the Group’s employees, which is an absolute priority. We are also aware of our responsibility, as a health care company, to ensure that our medicines remain available to patients.

Since January, a Group crisis unit has been dedicated to monitoring the situation and following its evolution. All our decisions take into account the directives of local health authorities and the governments of each country where the Group operates.

It has been decided that the implementation of the home office become widespread within the Group and is mandatory in the countries where containment measures are in place.

Specific measures have been taken to continue the activities at our production and R&D sites, while respecting health and safety conditions for employees whose presence is essential to the continuity of activities.

All these measures are in force until further notice. They may be adapted as the situation develops and in accordance with the directives of the authorities.

Our Group is thus fully mobilized to participate in the fight against the spread of the virus, while maintaining, as much as possible, the production and availability of our medicines for patients.

Last news

News
23/06/2022
Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
News
15/06/2022
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
News
01/06/2022
Patient associations’ perception of pharmaceutical companies: Servier is making progress!